Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Allfunds Bank to acquire Nordic Fund Market
Mandate

Allfunds Bank to acquire Nordic Fund Market

March 29, 2019 M&A

Vinge has advised Allfunds Bank (“Allfunds”) in connection with entering into an agreement to acquire Nordic Fund Market ("NFM") from Nasdaq.

Allfunds is the leading institutional fund and wealthtech platform in Europe with more than €370 billion of AuA. NFM is an electronic mutual fund service that enables straight through processing of orders and settlements. The service enables the fund distributors to access a broad choice of mutual funds through one single interface. There are presently around 200 connected fund companies with more than 5,000 mutual funds available on the Nasdaq platform. Completion of the transaction is subject to customary conditions.

Vinge’s team consisted of, among others, Jonas Bergström and Carl Sander (M&A), Emma Stuart-Beck, Henrik Schön and Mikaela Lang (Financial Regulatory), Ulf Nilsson and Victor Ericsson (Tax), and Nicklas Thorgerzon (TSA/CA).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026